-
1
ctDNA can help identify eligibility for endocrine therapy in older women.
-
2
Study analyzed 43 patients aged 70 and older.
-
3
Persistent ctDNA indicates tumor progression after therapy.
-
4
Negative ctDNA suggests stability and low progression risk.
-
5
Testing can be done through routine blood draws from home.
-
6
ctDNA may personalize treatment and minimize invasive procedures.
-
7
Need for validation in larger trials before practice changes.
-
8
Immune-related features were found in progressing tumors.
Original Source(s)
Related Content
‘Prostate Screening Saved My Life’—Is That Really True in Most Cases?
Prostate specific antigen (PSA) screening remains one of the most controversial of “standard” medical practices. As recently as the 2026 Super Bowl, one of the more unusual TV advertisements, sponsore...
March 31, 2026
-
7 min
Adjuvant Pembrolizumab Plus Belzutifan in Patients With RCC at Increased Risk of Recurrence
“Adjuvant pembrolizumab plus belzutifan demonstrated a statistically significant and clinically meaningful improvement in disease-free survival vs pembrolizumab plus placebo in patients with clear cel...
by Jo Cavallo
March 31, 2026
-
4 min
Advancing Precision Oncology: What Pooled Trial Data Reveal About 177 Lu-PSMA-617 in mCRPC
Radiopharmaceutical therapy is rapidly reshaping the treatment landscape for advanced prostate cancer.
